RBD-Fc fusion protein based on new coronavirus delta strain and application of RBD-Fc fusion protein

The invention discloses an RBD-Fc fusion protein based on a new coronavirus delta strain and application of the RBD-Fc fusion protein, a subunit vaccine prepared from the RBD-Fc fusion protein based on the new coronavirus delta strain can induce a mouse to generate a high-titer specific IgG antibody...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	ZHU HANPING, LUO YUANYUAN, LU HANGJING, YAO PINGPING, ZHOU ZHAN, ZHAO WENBIN, SUN YISHENG, XU FANG
Format:	Patent
Sprache:	chi ; eng
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The invention discloses an RBD-Fc fusion protein based on a new coronavirus delta strain and application of the RBD-Fc fusion protein, a subunit vaccine prepared from the RBD-Fc fusion protein based on the new coronavirus delta strain can induce a mouse to generate a high-titer specific IgG antibody and a neutralizing antibody, and the high-titer antibody level can last for 7 months. Meanwhile, the mouse can be induced to generate specific cellular immune response. 本发明公开了一种基于新冠病毒德尔塔株的RBD-Fc融合蛋白及其应用，该基于新冠病毒德尔塔株的RBD-Fc融合蛋白制备的亚单位疫苗可诱导小鼠产生高滴度的特异性IgG抗体和中和抗体，高滴度抗体水平可持续7个月，同时还能诱导小鼠产生特异的细胞免疫反应。